SPRB
Spruce Biosciences, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveSpruce Biosciences is advancing TA-ERT toward a transformative Q4 2026 BLA submission for MPS IIIB with strengthened clinical leadership, doubled cash position ($96.3M), and $5.5M in patient-advocacy funding support. The company maintains strong analyst consensus (Strong Buy, $158 average price target) despite modest valuation pressure from April equity dilution.
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | −18K | 1.9% | +0.5% vs SPY -1.2% abs | 2026-08-14 | ↗ |
| Citadel Advisors | SC 13G/A | — | 5.1% | -13.0% vs SPY -7.5% abs | 2026-05-15 | ↗ |
| Citadel Advisors | SC 13G/A | — | 6.5% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 28K | $2M |
Quarter-end 13F positions for the tracked funds holding this stock.